Comparison · NCT00740051-sae
Linagliptin vs Placebo/Glimepiride: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Linagliptin vs Placebo/Glimepiride: serious adverse events. Trial comparisons, record NCT00740051-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00740051-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.00662 | 0.00117 | 0.0366 | wilson | |
| Risk in group 2 | 0.0395 | 0.0135 | 0.11 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0329 | -0.103 | 0.00677 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.168 | 0.0177 | 1.59 | log | |
| Odds ratio, group 1 over group 2 | 0.162 | 0.0166 | 1.59 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Linagliptin than on Placebo/Glimepiride | 30.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Linagliptin | Patients treated with Linagliptin 5mg once daily (up to 52 weeks) | 1 | 151 | EG001 |
| Group 2 | Placebo/Glimepiride | Patients treated with matching placebo (up to 18 weeks) followed by Glimepiride (after 18 weeks to 52 weeks) | 3 | 76 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- 52 weeks + 7 days
Source ClinicalTrials.gov
Trial
- Title
A Randomised, db, Placebo-controlled Study of BI 1356 for 18 Weeks Followed by a 34 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Type 2 Diabetic Patients for Whom Treatment With Metformin is Inappropriate
- NCT number
- NCT00740051
- Phases
- PHASE3
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Linagliptin, Linagliptin Placebo, Glimepiride
- Lead sponsor
- Boehringer Ingelheim
- Results first posted
- 2011-10-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00740051?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00740051-sae